Telix Pharmaceuticals (TLPPF)
Jefferies analyst David Stanton maintained a Buy rating on Telix Pharmaceuticals on August 21 and set a price target of A$29.30. The company’s shares closed last Friday at $10.20, close to its 52-week low of $8.14.
According to TipRanks.com, Stanton is a 4-star analyst with an average return of 14.6% and a 51.2% success rate. Stanton covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals, and Pro Medicus Limited.
Currently, the analyst consensus on Telix Pharmaceuticals is a Strong Buy with an average price target of $18.17, implying a 78.1% upside from current levels. In a report issued on August 20, TipRanks – PerPlexity also upgraded the stock to Buy with a A$18.50 price target.
See today’s best-performing stocks on TipRanks >>
